Effect of proteinase inhibitor camostat mesilate on nephrotic syndrome with diabetic nephropathy.
The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.
Onbe
T
T
Third Department of Medicine, Okayama University Medical School, Japan.
Makino
H
H
Kumagai
I
I
Haramoto
T
T
Murakami
K
K
Ota
Z
Z
D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000032:analysis; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004487:Edema; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D007677:Kidney Function Tests; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011507:Proteinuria
D001798:Blood Proteins; D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D016670:Gabexate